The top enriched pathways included pathways that are associated with cell proliferation (mTORC1 signaling, MYC targets V1) and therapy response of breast cancer (estrogen response early, estrogen response late) (Figure 2D), which are compatible with the patients’ clinicopathological features and more malignant traits of EDC clusters. Here, MYC is linked to breast carcinoma.